Public Health Key Documents: February 2025

NIHR

Nil

The King's Fund

Lost In The System: The Need For Better NHS Admin

Nearly 2 in 3 patients and carers in England have experienced at least one admin problem over the last year such as lost test results, inability to change or cancel appointments, or receiving incorrect information. 1 in 5 people received an appointment invitation after the date of the appointment. Of those who faced admin issues, 4 in 10 say they are less likely to seek care in the future. Carers, patients with long-term health conditions, people from ethnic minority backgrounds and those struggling financially were all significantly more likely to experience issues with NHS admin and communication.

Systematic search: No

February 2025

Designing Inclusive Digital Health Services with Communities

Digital health and care services have huge potential to transform care and provide data insights on patients' needs - but to realise this potential they must be truly inclusive. The NHS needs to avoid tick-box engagement and make it meaningful, balance power dynamics, support staff and make engagement a sustainable reality. Senior leaders have a role to play alongside policy-makers to embed patient voice in the work to develop a digital NHS, build up the capability and set out a vision for data-rich insights explored through trailblazer-type initiatives.

Systematic search: No

February 2025

SIGN

Nil

Public Health Scotland

<u>Early evidence of population impact of RSV vaccination on hospitalisations among older adults in Scotland</u>

Age groups eligible for the vaccine (75 to 79 years old) had a significantly reduced rate of hospitalisation compared to those who were not eligible.

Systematic search: No

February 2025

Scottish Government

Maternity pathway and schedule of care: clinical guidance and schedule

This pathway illustrates the core care that women and their babies should receive. All core contacts antenatally and postnatally (other than 32 weeks antenatal visit for primigravid and parous as required) should be face to face as they include physical examination.

Systematic search: No

February 2025

Mental health - distress framework for collaboration: multi-agency partnership approach

The framework has been developed by the Scottish Government with Partnership Delivery Group (PDG) members. It sets out principles for a multi-agency collaborative approach to supporting individuals experiencing distress or crisis.

Systematic search: No

February 2025

Mental Health Partnership Delivery Group: collaborative commitments plan

The Partnership Delivery Group's cross-sector collaborative commitments plan sets out actions across priority themes to improve the multi-agency approach to supporting those experiencing mental health distress.

Systematic search: No

February 2025

Scottish Medicines Consortium (SMC Advice)

fenfluramine (Fintepla)

Accepted for restricted use within NHSScotland for the treatment of seizures associated with Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older. Restricted to patients whose seizures have not been controlled after trying two or more anti-epileptic medicines.

Systematic search: No

February 2025

lecanemab (Legembi)

NOT recommended for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ϵ 4 (ApoE ϵ 4) heterozygotes or non-carriers.

Systematic search: No

February 2025

netarsudil / latanoprost (Roclanda)

Accepted for restricted use for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.

Systematic search: No

February 2025

cemiplimab (Libtayo)

Accepted for use as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Systematic search: No

February 2025

cabotegravir (Apretude)

Cabotegravir prolonged-release injection and Cabotegravir tablets are accepted in limited specific circumstances, in combination with safer sex practices, for short term pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg.

Systematic search: No

February 2025

durvalumab (Imfinzi)

Accepted for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

Systematic search: No

February 2025

olaparib (Lynparza)

Accepted for use as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer in specific limited circumstances.

Systematic search: No

February 2025

NICE - Technology Appraisal Guidance

TA1033 Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over

Systematic search: No

February 2025

TA1038 <u>Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over</u>

Systematic search: No

February 2025

TA1039 <u>Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over</u>

Systematic search: No

February 2025

TA1040 <u>Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy</u>

Systematic search: No

February 2025

TA1037 Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer

Systematic search: No

February 2025

TA1036 <u>Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer</u> with an ESR1 mutation after endocrine treatment

Systematic search: No

February 2025

NICE – Guidelines

Nil

UKHSA

Nil

Health and Care Research Wales Evidence Centre

EPPI Centre

Nil

AHRQ (Agency for Healthcare Research and Quality - USA)

Nil

Health Foundation

The preventative shift: how can we embed prevention and achieve long term missions

This briefing, published with Demos, examines how to shift the culture of public bodies to think 'prevention first' and target spending at activities which are value for money and improve outcomes.

Systematic search: No

February 2025

Canadian Agency for drugs and Technologies in Health (CADTH)

Association Between Opioid Use and the Development of Diverticulitis

A comparative safety study was conducted to assess the risk of diverticulitis associated with short-term and long-term opioid use in patients treated for various pain indications. The primary analysis included 23,084,410 patients with postsurgical pain indication across 5 Canadian provinces, the UK, and US. Starting opioid treatment within 7 days of surgery and continuing through the follow-up period was linked to higher rates of all diverticulitis and severe diverticulitis, though only the increase in severe diverticulitis was statistically significant. Additional analyses showed larger increases in diverticulitis rates for trauma and other pain indications compared to the postsurgical group. Health care providers may need to be particularly cautious with long-term opioid use and monitor for signs of diverticulitis, despite low overall rates in the general population. Findings should be interpreted with an understanding of the study's assumptions and limitations.

Systematic search: Limited

February 2025

McGill University Health Centre (Canada)

Nil

Health Information & Quality Authority (Ireland) – Health Technology Assessments

Nil

Campbell Collaboration

Nil

Glasgow Centre for Population Health

Nil

Selected other recent reports

Centre for Mental Health et al. (2025) <u>Future Minds Report: Why investing in children's mental health will unlock economic growth</u>

More than one in five children and young people in England now have a diagnosable mental health condition. The NHS is only able to support around 40% of those in need. This report puts forward

suggestions for closing this treatment gap and providing earlier support that prevents problems from escalating.

Joseph Rowntree (2025) <u>UK Poverty 2025: The essential guide to understanding poverty in the UK</u> This report sets out the nature of poverty in the UK in the run-up to 2024's General Election. It also sets out the scale of action necessary for the Government to deliver the change it has promised.

Nuffield Council on Bioethics (2025) <u>Climate change and health: embedding ethics into policy and decision-making</u>

This report explores the importance of integrating ethics into measures that address anthropogenic climate change. It aims to inform policy development and decision-making in the UK, highlighting the need to address the intersections between climate change and health.

Reform UK (2025) Innovating for independence: a win-win for health and social care

Emerging innovative technologies have the potential to significantly improve the delivery of social care in the short-term. This can be done via monitoring an individual's health and wellbeing, enabling earlier intervention, personalising care packages and in turn, boosting capacity. Realising these benefits would be a 'win-win-win' for those receiving care, local authorities and the NHS. This briefing paper explores the barriers that are preventing proven technologies being scaled up and makes recommendations to allow this to happen.

Royal Society for Public Health (2025) What Are You Talking About: Using everyday conversations to improve health outcomes

The report calls for the widespread roll out of the Making Every Contact Count (MECC) approach across everyday settings including workplaces, care homes, gyms and schools. MECC trains professionals to help them integrate conversations about health and wellbeing into routine practice. These conversations encourage and support the public to make healthy behaviour changes, and signpost them to relevant information. It argues that small behaviour changes will have an impact on the overall health of the UK and help to reduce pressure on the NHS. It also calls for more preventative health measures to be implemented to intervene early and influence behaviour.

NICE FORWARD PLANNING - Publications due March 2025

Ovarian cancer QS update

CancerQuality Standard - update (new clinical practice evidence)

Falls: assessment and prevention in older people and people 50 and over at higher risk (update) Clinical Guideline - update (new clinical practice evidence)

Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment

Technology Appraisal

12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834)

Technology Appraisal

Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable

Technology Appraisal

Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Technology Appraisal